Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients

Pamela Samson,Clifford Robinson,Jeffrey Bradley,A. Craig Lockhart,Varun Puri,Stephen Broderick,Daniel Kreisel,A. Sasha Krupnick,G. Alexander Patterson,Bryan Meyers,Traves Crabtree

DOI: https://doi.org/10.1016/j.jtho.2016.07.031

IF: 20.121

2016-12-01

Journal of Thoracic Oncology

Abstract:OBJECTIVES: The aim of this study was to evaluate differences in pathologic complete response (pCR) rates and overall survival among patients receiving either neoadjuvant chemotherapy or chemoradiation before esophagectomy for locally advanced esophageal cancer.METHODS: Patients with esophageal cancer receiving either neoadjuvant chemotherapy or chemoradiation before esophagectomy were identified using the National Cancer Database. Univariate analysis compared patient, tumor, and postoperative outcome characteristics. Logistic regression was performed to identify variables associated with achieving pCR. Kaplan-Meier analysis was performed to compare overall median survival by neoadjuvant therapy type and pCR status. Finally, a Cox proportional hazards model was fitted to identify variables associated with increased mortality hazard.RESULTS: From 2006 to 2012, a total of 916 of 7338 of patients (12.5%) received neoadjuvant chemotherapy whereas 6422 (87.5%) received neoadjuvant chemoradiation. Patients who received neoadjuvant chemoradiation were more likely to achieve a pCR (17.2% versus 6.4%, p < 0.001) and less likely to have positive margins (5.6% versus 11.5%, p < 0.001) than were patients who received neoadjuvant chemotherapy, with no difference in 30- or 90-day mortality. Achieving a pCR was associated with improved overall median survival (59.5 ± 4.0 months versus 30.1 ± 0.76 months for those with persistent disease, p < 0.001). On logistic regression, neoadjuvant chemoradiation therapy was independently associated with achieving a pCR (OR = 2.75, 95% confidence interval: 2.01-3.77, p < 0.001). Despite improvement in the pCR rate with neoadjuvant chemoradiation, neoadjuvant therapy type was not independently associated with long-term survival (hazard ratio = 1.12; 95% confidence interval: 0.97-1.30, p = 0.12).CONCLUSIONS: Although neoadjuvant chemoradiation is more successful in downstaging esophageal cancer before esophagectomy, it was not independently prognostic for improved long-term survival. Other factors affecting long-term survival among pathologic complete responders and among patients with persistent disease should be investigated to clarify this association.

oncology,respiratory system

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the difference in the impact of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy on the pathological complete response rate (pCR) and overall survival rate in esophageal cancer patients before esophagectomy. Specifically, the researchers hope to explore the following aspects by analyzing the data in the National Cancer Database (NCDB):

1. **Practice of neoadjuvant treatment modalities**: In the United States, what are the usage and related results of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy in patients with locally advanced esophageal cancer?
2. **Comparison of pathological complete response rate (pCR)**: Is neoadjuvant chemoradiotherapy more likely to improve the pathological complete response rate of patients than neoadjuvant chemotherapy?
3. **Difference in overall survival rate**: Is there a significant difference in overall survival rate between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy?

Through these analyses, the researchers hope to provide more evidence for clinicians to guide the treatment selection of patients with locally advanced esophageal cancer.